



August 8, 2022

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 543524

Sub: Outcome of the Board Meeting held on August 8, 2022.

Ref: Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations") read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Dear Sir/ Madam,

In reference to the above referred provisions, please take note that the Board of Directors of Rainbow Children's Medicare Limited ("**the Company**") in their meeting held today i.e. August 8, 2022, inter-alia, considered and approved the following matters:

1. The unaudited Standalone and Consolidated Financial Results ("**Results**") of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith.
2. Convening of 24th Annual General Meeting ("**AGM**") of the Company on Thursday September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM).
3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM).



Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034

Corporate Office: 8-2-19/1/a, Dault Arcade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana - 500034

Hyderabad: Banjara Hills - 040 22334455 | Secunderabad - 040 42462200 | Kondapur IP - 040 42462400 |
Kondapur OP - 040 42462100 | Hyder Nagar - 040 42462300 | L B Nagar - 040 71111333

Vijayawada: Currency Nagar - 0866 6669666 | Governorpet - 0866 6650250 | **Chennai:** Guindy - 044 40122444

Bengaluru: Marathahalli - 080 71112345 | Bannerghatta Road - 080 25512345 | Hebbal - 080 35061555

Delhi: Malviya Nagar - 011 66888866 | **Visakhapatnam:** Health City, Chinagadili - 0891 3501601 | Siripuram - 0891 3501555

Symbol	Type of Security	Book Closure both days inclusive	Record date	Purpose
NSE - RAINBOW BSE - 543524	Equity	Not Applicable	Thursday, September 8, 2022	1. 24 th Annual General Meeting. 2. Payment of Final Dividend, if approved at the ensuing AGM.

Dividend if declared at the ensuing AGM shall be paid within a period of 30 days from the date of declaration.

4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM.

The details of the reclassification of Authorised Share Capital is described below:

"Reclassification of Authorized Share Capital from INR. 150,00,00,000 divided into (a) 13,90,55,616 Equity Shares of INR 10/- each (b) 11,46,771 - Series A 0.0001% Compulsorily Convertible Preference Shares ("Series A CCPS") of INR. 48/- each and (c) 11,33,309 Series B 0.0001% Compulsorily Convertible Preference Shares ("Series B CCPS") of INR. 48/- to INR. 150,00,00,000 divided into 15,00,00,000 Equity Shares of INR 10/- each."

The Board Meeting commenced at 12:30 P.M. and concluded at 2:10 P.M.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**


Ashish Kapil

Company Secretary and Compliance Officer



Encl.: As above

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors of Rainbow Children's Medicare Limited
(Formerly known as 'Rainbow Children's Medicare Private Limited')**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') ("the Company") for the quarter ended 30 June 2022 ("the Statement").

Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2021, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company during the quarter ended 30 June 2022.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the unpublished audited year to date figures up to the third quarter of the previous financial year.



B S R & Associates LLP

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231W/W-100024



Jhahanwijha Shyamsukha

Partner

Membership No.: 064550

UDIN:22064550AOMVFB9982

Hyderabad

08 August 2022

Rainbow Children's Medicare Limited (formerly known as "Rainbow Children's Medicare Private Limited")

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Corporate Office : 8-2-19/1/a, Danlet Archade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2022

Particulars	(Rs. in Millions except per share data)			
	Quarter ended		Year ended	
	30 June 2022	31 March 2022	30 June 2021	31 March 2022
	Unaudited Refer Note 2	Audited Refer Note 3	Unaudited Refer Note 4	Audited
INCOME				
1. Revenue from operations	2,227.53	2,011.47	2,362.05	9,245.95
2. Other income	64.07	65.98	26.64	208.19
3. Total income [1+2]	2,291.60	2,077.45	2,388.69	9,454.14
4. EXPENSES				
a. Medical consumables and pharmacy items consumed	296.85	320.32	575.98	1,877.98
b. Employee benefits expense	287.23	298.91	235.62	1,094.12
c. Finance costs	134.29	154.86	121.91	500.05
d. Depreciation and amortisation expense	202.95	206.87	177.72	769.87
e. Professional fees to doctors	523.65	496.48	500.36	1,857.80
f. Other expenses	345.21	426.01	281.70	1,456.88
Total expenses	1,790.18	1,903.45	1,893.29	7,556.70
5. Profit before tax [3-4]	501.42	174.00	495.40	1,897.44
6. Tax expenses:				
a. Current tax	150.13	55.47	150.22	575.48
b. Deferred tax credit	(24.66)	(25.90)	(28.08)	(100.95)
Total tax expense	125.47	29.57	122.14	474.53
7. Profit for the period/year [5-6]	375.95	144.43	373.26	1,422.91
8. Other comprehensive income				
<i>Items that will not be reclassified to profit or loss</i>				
Re-measurement gain on defined benefit plans	6.36	3.88	1.47	13.02
Income tax relating to items that will not be reclassified to profit or loss	(1.60)	(0.98)	(0.37)	(3.28)
Other comprehensive income for the period/year, net of tax	4.76	2.90	1.10	9.74
9. Total comprehensive income for the period/year [7+8]	380.71	147.33	374.36	1,432.65
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.02	1,049.98	549.03	1,049.98
11. Other equity				5,312.95
12. Earning per share (Face value of Rs.10 each) (not annualised for the quarters)				
a. Basic (Rs)	3.72	1.61	4.06	15.18
b. Diluted (Rs)	3.72	1.57	3.97	14.87



Notes :

- 1 The standalone financial results of Rainbow Children's Medicare Limited (formerly known as Rainbow Children's Medicare Private Limited) ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the 'Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above standalone financial results of the company, for the quarter ended 30 June 2022 were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 08 August 2022.
- 3 The standalone figures for the quarter ended 31 March 2022 are the balancing figures between the audited standalone figures in respect of the full previous financial year and the unpublished audited year to date standalone figures up to the third quarter of the previous financial year.
- 4 The standalone figures for the quarter ended 30 June 2021 as reported in these standalone financial results were neither reviewed nor subject to audit, however, the management has exercised necessary due diligence to ensure that the standalone financial results for these period provide a true and fair view of the Company's affairs.
- 5 During the period, the Board of Directors of the Company in their meeting held on 04 April 2022, approved conversion of (i) 1,146,771 0.0001% Series A Compulsorily Convertible Preference Shares (CCPS) of face value of Rs. 48 each into 1,146,771 Equity Shares of Rs. 10 each and (ii) 1,133,309 0.0001% Series B Compulsorily Convertible Preference Shares of face value of INR 48 each into 1,133,309 Equity Shares of Rs. 10 each, at a conversion ratio of 1:1, ranking pari passu with the existing Equity Shares of the Company.
- 6 During the period, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) i.e. 10 May 2022.

The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted to securities premium.

Details of utilisation of IPO proceeds:**(Rs. in Millions)**

Objects of the Issue	Amount as proposed in offer document	Utilisation up to 30 June 2022	Unutilised amount as at 30 June 2022
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	13.06	1,686.94
General Corporate Purposes	561.40	-	561.40
Total	2,661.40	413.06	2,248.34

Net IPO proceeds which were un-utilised as at 30 June 2022 were temporarily invested in fixed deposits with banks (held in cash and bank balances).

- 7 Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
- 8 The results for the three month period ended 30 June 2022, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the company's website (URL: www.rainbowhospitals.in).

*for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited*



Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 08 August 2022

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited')

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2021, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Parent during the quarter ended 30 June 2022.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') (**Parent**)

Subsidiaries

- b. Rainbow Speciality Hospitals Private Limited
- c. Rosewalk Healthcare Private Limited
- d. Rainbow C R O Private Limited

Registered Office:

B S R & Associates LLP

- e. Rainbow Fertility Private Limited
 - f. Rainbow Children's Hospital Private Limited
 - g. Rainbow Women and Children's Hospitals Private Limited
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the unpublished audited year to date figures up to the third quarter of the previous financial year.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial results of six subsidiaries which have not been reviewed, whose interim financial results reflect total revenues of Rs. 146.95 million, total net profit after tax of Rs.11.65 million and total comprehensive income of Rs. 12.16 million, for the quarter ended 30 June 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231W/W-100024

J Shyamsukha

Jhahanwijha Shyamsukha

Partner

Hyderabad

08 August 2022

Membership No.: 064550

UDIN:22064550AOMVVM1990

Rainbow Children's Medicare Limited (formerly known as "Rainbow Children's Medicare Private Limited")

CIN: L851101G1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034
Corporate Office : 8-2-19/1/a, Daulat Archade, Karyy lane, Road No.11, Banjara Hills, Hyderabad, Telangana-500034

Tel: 491 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2022

Particulars	(Rs. in Millions except per share data)			
	Quarter ended		Year ended	
	30 June 2022	31 March 2022	30 June 2021	31 March 2022
	Unaudited Refer Note 2	Audited Refer Note 3	Unaudited Refer Note 4	Audited
INCOME:				
1. Revenue from operations	2,371.52	2,124.47	2,463.57	9,737.58
2. Other income	60.33	61.86	21.35	189.37
3. Total income [1+2]	2,431.85	2,186.33	2,484.92	9,926.95
4. EXPENSES				
a. Medical consumables and pharmacy items consumed	318.02	337.61	588.30	1,947.29
b. Employee benefits expense	305.38	317.13	251.47	1,160.71
c. Finance costs	142.16	162.78	129.98	532.03
d. Depreciation and amortisation expense	219.12	222.82	193.13	832.63
e. Professional fees to doctors	562.12	535.36	544.88	2,037.60
f. Other expenses	365.09	453.04	296.28	1,543.23
Total expenses	1,911.89	2,028.74	2,004.04	8,053.49
5. Profit before tax [3-4]	519.96	157.59	480.88	1,873.46
6. Tax expenses:				
a. Current tax	156.40	55.62	150.43	576.13
b. Deferred tax credit	(24.05)	(20.63)	(28.35)	(89.40)
Total tax expense	132.35	34.99	122.08	486.73
7. Profit for the period/year [5-6]	387.61	122.60	358.80	1,386.73
8. Other comprehensive income				
<i>Items that will not be reclassified to profit or loss</i>				
Re-measurement gain on defined benefit plans	6.93	4.19	1.61	13.63
Income tax relating to re-measurement gain on defined benefit plans	(1.65)	(1.02)	(0.39)	(3.36)
Other comprehensive income for the period/year, net of tax	5.28	3.17	1.22	10.27
9. Total comprehensive income for the period/year [7+8]	392.89	125.77	360.02	1,397.00
Profit for the period/year attributable to:				
Owners of the Company	381.89	121.94	359.33	1,382.66
Non-controlling interests	5.72	0.66	(0.53)	4.07
Profit for the period/year	387.61	122.60	358.80	1,386.73
Other comprehensive income for the period/year attributable to:				
Owners of the Company	5.25	3.15	1.21	10.23
Non-controlling interests	0.03	0.02	0.01	0.04
Other comprehensive income for the period/year	5.28	3.17	1.22	10.27
Total comprehensive income for the period/year attributable to:				
Owners of the Company	387.14	125.09	360.54	1,392.89
Non-controlling interests	5.75	0.68	(0.52)	4.11
Total comprehensive income for the period/year	392.89	125.77	360.02	1,397.00
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.02	1,049.98	549.03	1,049.98
11. Other equity				4,978.06
12. Earning per share (Face value of Rs.10 each) (not annualised for the quarters)				
- Basic (Rs)	3.78	1.36	3.91	14.75
- Diluted (Rs)	3.78	1.33	3.82	14.45



Notes :

- The consolidated financial results of Rainbow Children's Medicare Limited (formerly known as Rainbow Children's Medicare Private Limited) ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated financial results for the quarter ended 30 June 2022 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08 August 2022.
- The consolidated figures for the quarter ended 31 March 2022 are the balancing figures between the audited consolidated figures in respect of the full previous financial year and the unpublished audited year to date consolidated figures upto the third quarter of the previous financial year.
- The consolidated figures for the quarter ended 30 June 2021 as reported in these consolidated financial results were neither reviewed nor subject to audit, however, the management has exercised necessary due diligence to ensure that the consolidated financial results for these period provide a true and fair view of the Company's affairs.
- During the period, the Board of Directors of the Company in their meeting held on 04 April 2022, approved conversion of (i) 1,146,771 0.0001% Series A Compulsorily Convertible Preference Shares (CCPS) of face value of Rs. 48 each into 1,146,771 Equity Shares of Rs. 10 each and (ii) 1,133,309 0.0001% Series B Compulsorily Convertible Preference Shares of face value of INR 48 each into 1,133,309 Equity Shares of Rs. 10 each, at a conversion ratio of 1:1, ranking pari passu with the existing Equity Shares of the Company.
- During the period, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.

The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted to securities premium.

Details of utilisation of IPO proceeds:**(Rs. in Millions)**

Objects of the issue	Amount as proposed in offer document	Utilisation up to 30 June 2022	Unutilised amount as at 30 June 2022
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	13.06	1,686.94
General Corporate Purposes	561.40	-	561.40
Total	2,661.40	413.06	2,248.34

Net IPO proceeds which were un-utilised as at 30 June 2022 were temporarily invested in fixed deposits with banks (held in cash and bank balances).

- The results for the three month period ended 30 June 2022, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the company's website (URL: www.rainbowhospitals.in).
- The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- The consolidated financial results include the financial results of Rainbow Children's Medicare Limited (parent company) and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited and Rainbow Children's Hospital Private Limited (together called as the "Group").

*for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited*




Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 08 August 2022